Notice of Extraordinary General Meeting of Senzime for the introduction of an employee stock option program

Uppsala, August 31, 2017. Senzime AB (publ) calls for an Extraordinary General Meeting for the introduction of an employee stock option program. The Board proposes that the General Meeting approve resolutions to issue no more than 1,300,000 warrants and to introduce an employee stock option plan. 

The options require employment in the Company and are not transferable. The dilution resulting from the proposed program will be no more than 3.2 percent of the existing shares and votes, based on the existing number of shares and assuming that all outstanding warrants are exercised before the new subscription.

The Board believes that it is important and in the interests of all shareholders that its employees, who are important for the Company's future development, have long-term incentive to grow the value of the Company's shares.  A personal commitment to long-term ownership can be expected to motivate improvements in the Company's operations and development of its earnings, enhancing participants' alignment with Company growth and shareholders interests.

The Extraordinary General Meeting will take place on Friday 15 September 2017 at 15:00 in the premises of Advokatfirman Lindahl, Vaksalagatan 10, Uppsala. Full notice (only in Swedish) is now available on the company's website www.senzime.com 

For further information, please contact: 

Lena Söderström, CEO of Senzime AB

Tel: +46 708-16 39 12, email: lena.soderstrom@senzime.com 

TO THE EDITORS  

About Senzime  

Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North (ticker SEZI). FNCA is Certified Adviser for Senzime. www.senzime.com 

The information was submitted for publication through the agency of the contact person set out above, on August 31, 2017.

About Us

Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North (ticker SEZI). FNCA is Certified Adviser for Senzime. www.senzime.com

Subscribe

Documents & Links